ArticleOncoTargets and therapy2019
G-protein-signaling modulator 2 expression and role in a CD133
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- [GPSM2 is highly expressed in gastric cancer to affect patient prognosis by promoting tumor cell proliferation].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Cancer stem cells: advances in knowledge and implications for cancer therapy.Signal transduction and targeted therapy · 2024Review
- Article
- Yin Yang 1-induced activation of LINC01133 facilitates the progression of pancreatic cancer by sponging miR-199b-5p to upregulate myelin regulatory factor expression.Bioengineered · 2022Article
- Migration and homeostasis of regulatory T cells in rheumatoid arthritis.Frontiers in immunology · 2022Review
- A comprehensive analysis of G-protein-signaling modulator 2 as a prognostic and diagnostic marker for pan-cancer.Frontiers in genetics · 2022Article
- Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas.Brain sciences · 2021Article
- Identifying GPSM Family Members as Potential Biomarkers in Breast Cancer: A Comprehensive Bioinformatics Analysis.Biomedicines · 2021Article
- Identification of an extracellular vesicle-related gene signature in the prediction of pancreatic cancer clinical prognosis.Bioscience reports · 2020Article
- Knockdown of G-protein-signaling modulator 2 promotes metastasis of non-small-cell lung cancer by inducing the expression of Snail.Cancer science · 2020Article
- Localization of GPSM2 in the Nucleus of Invasive Breast Cancer Cells Indicates a Poor Prognosis.Frontiers in oncology · 2020Article
- GPSM2 Serves as an Independent Prognostic Biomarker for Liver Cancer Survival.Technology in cancer research & treatmentArticle
Corrections and comments
- Retraction · 2024-08-14Concerns/Issues about Third Party Involvement · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Paper Mill · Plagiarism of Image · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the expression and role of G-protein-signaling modulator 2 (GPSM2) in a CD133 MATERIALS AND
methodsPancreatic cancer stem cells (PCSCs) from the cell line PANC-1 were sorted into CD133
resultsCD133
conclusionThe CD133
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.